Paeonol-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEPaeonolCat.No.:HY-N0159CASNo.:552-41-0分?式:C?H??O?分?量:166.17作?靶點:MonoamineOxidase;Autophagy作?通路:NeuronalSignaling;Autophagy儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗Ethanol:50mg/mL(300.90mM;Needultrasonic)DMSO:≥38mg/mL(228.68mM)H2O:1mg/mL(6.02mM;Needultrasonic)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲備液1mM6.0179mL30.0897mL60.1793mL5mM1.2036mL6.0179mL12.0359mL10mM0.6018mL3.0090mL6.0179mL請根據(jù)產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內使?，-20°C儲存時，請在1個?內使?。體內實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(15.04mM);Suspendedsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(15.04mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(15.04mM);Clearsolution4.請依序添加每種溶劑：10%EtOH>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(15.04mM);Clearsolution5.請依序添加每種溶劑：10%EtOH>>90%cornoilSolubility:≥2.5mg/mL(15.04mM);ClearsolutionBIOLOGICALACTIVITY?物活性Paeonol牡丹根的活性提取物，Paeonol抑制MAO-A和MAO-B，IC50分別為54.6μM和42.5μM。IC50&TargetIC50:42.5μM(MAO-B),54.6μM(MAO-A)[1]體外研究PaeonolisfoundtobeinhibitoryagainstMAOAinadose-dependentmannerwithIC50valueof54.6μM.PaeonolisshowntoinhibitMAO-Binadose-dependentmannerwiththeIC50of42.5μM.ForPaeonol,theKiisestimatedtobe51.1μM.TheinhibitionofPaeonolonMAOBisofcompetitivetypewithKivalueof38.2μM[1].體內研究The200mg/kgPaeonol+I/Rgroup[AN/V(%):7.6±2.2,p[2].PROTOCOLAnimalMice[2]Administration[2]MaleWistarrats(180-220g,averageageof8week)arerandomlydividedintofourgroups:(1)shamgroup,thoracotomywithoutleftanteriordescendingcoronaryartery(LAD)occlusionorPaeonolpretreatment;(2)I/Rgroup,LADocclusion(ischemia)for4hfollowedbyreperfusionfor8h;(3)Paeonol(100mg/kg)+I/Rgroup,oraladministrationof100mg/kgPaeonol(1mL/kg)for7daysusingaintragastrictubepriortoI/Rprocedure;(4)Paeonol(200mg/kg)+I/Rgroup,oraladministrationof200mg/kgPaeonol(1mL/kg)for7daysusingaintragastrictubepriortoI/Rprocedure.Inaddition,ratsintheshamandI/RgroupsreceivedadosageofDMSOequaltothatwithwhichthePaeonolwasdissolvedinfortheothertwogroups.DMSOwasalsoadministeredintragastricallyfor7consecutivedays.Aminimumofeightratswereassignedtoeachgroup.AnischemiagroupwithoutreperfusionisnotincludedsinceourpresentstudymainlyfocusesontheeffectofPaeonolonthecardiacinjuriesafterreperfusion,whichiscloselyrelatedtothereal-worldsituationofno-reflowaftercoronaryrevascularization.However,futurestudiesmayincludeagroupsubjectedonlyto4hofischemiatodifferentiate,intermsofdamagetothecardiacfunction,whichwasduetotheischemiaandwhichwasduetotheno-reflow.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE戶使?本產品發(fā)表的科研?獻?Metabolites.2022,12(10),956.?JInorgBiochem.2022Jan24;230:111733.?BiochemBiophysResCommun.2022Feb8;600:35-43.?ExpTherMed.November25,2021.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].KongLD,etal.InhibitionofMAOAandBbysomeplant-derivedalkaloids,phenolsandanthraquinones.JEthnopharmacol.2004Apr;91(2-3):351-5.[2].MaL,etal.PaeonolProtectsRatHeartbyImprovingRegionalBloodPerfusionduringNo-Reflow.FrontPhysiol.2016Jul21;7:298.McePdfH